ARGX

argenx NV ADR

ARGX, USA

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

https://argenx.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ARGX
stock
ARGX

Argenx Se (ARGX) Receives a Buy from Wells Fargo The Globe and Mail

Read more →
ARGX
stock
ARGX

(ARGX) Movement as an Input in Quant Signal Sets Stock Traders Daily

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$1016.4751

Analyst Picks

Strong Buy

14

Buy

7

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Low

34.95

Low 50

High 10

Investors

* Institutions hold a combined 58.91% of the total shares of argenx NV ADR

1.

FMR Inc

(8.862%)

since

2025/06/30

2.

T. Rowe Price Associates, Inc.

(8.1372%)

since

2025/06/30

3.

HHG PLC

(4.1918%)

since

2025/06/30

4.

Artisan Partners Limited Partnership

(3.8395%)

since

2025/06/30

5.

Capital World Investors

(3.188%)

since

2025/06/30

6.

venBio Select Advisor LLC

(1.9199%)

since

2025/06/30

7.

American Funds EUPAC A

(1.8239%)

since

2025/06/30

8.

Capital Group EUPAC Composite

(1.8239%)

since

2025/06/30

9.

Fidelity Growth Compy Commingled Pl S

(1.4224%)

since

2025/07/31

10.

Citadel Advisors Llc

(1.415%)

since

2025/06/30

11.

ClearBridge Advisors, LLC

(1.2629%)

since

2025/06/30

12.

T. Rowe Price Health Sciences

(1.15%)

since

2025/07/31

13.

RTW INVESTMENTS, LLC

(1.1005%)

since

2025/06/30

14.

US Small-Cap Growth II Equity Comp

(1.0201%)

since

2025/06/30

15.

Fidelity Growth Company Fund

(1.0185%)

since

2025/07/31

16.

BB Biotech AG Ord

(0.9657%)

since

2024/12/31

17.

Janus Concentrated Growth CF

(0.9359%)

since

2025/06/30

18.

Janus Henderson Forty S

(0.9359%)

since

2025/06/30

19.

Bellevue Group AG

(0.9331%)

since

2025/06/30

20.

T. Rowe Price US Growth Stock Composite

(0.903%)

since

2025/06/30

21.

BlackRock Inc

(0.8989%)

since

2025/06/30

22.

T. Rowe Price New Horizons

(0.8924%)

since

2025/07/31

23.

Fidelity OTC

(0.8053%)

since

2025/07/31

24.

T. Rowe Price Growth Stock Tr-B

(0.728%)

since

2025/06/30

25.

Millennium Management LLC

(0.7024%)

since

2025/06/30

26.

Morgan Stanley - Brokerage Accounts

(0.7015%)

since

2025/06/30

27.

Capital Group New Economy Comp

(0.67%)

since

2025/06/30

28.

American Funds New Economy A

(0.67%)

since

2025/06/30

29.

Wellington Management Company LLP

(0.6623%)

since

2025/06/30

30.

Bank of America Corp

(0.5492%)

since

2025/06/30

31.

SEI Investments Co

(0.517%)

since

2025/06/30

32.

T. Rowe Price Growth Stock

(0.5155%)

since

2025/07/31

33.

Janus Inst Mid Cap Growth CF

(0.51%)

since

2025/06/30

34.

Janus Henderson Enterprise D

(0.51%)

since

2025/06/30

35.

Adage Capital Partners Gp LLC

(0.4855%)

since

2025/06/30

36.

Artisan U.S. Mid-Cap Growth

(0.475%)

since

2025/06/30

37.

Artisan Mid Cap Investor

(0.475%)

since

2025/06/30

38.

Franklin Resources Inc

(0.4572%)

since

2025/06/30

39.

Jennison Associates LLC

(0.4324%)

since

2025/06/30

40.

Amvescap Plc.

(0.3983%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

6.1

Latest Release

Date

2025-09-30

EPS Actual

5.18

EPS Estimate

4.44

EPS Difference

0.74

Surprise Percent

16.6667%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1)
Defensive
Cyclical / Risky(3)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(6)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1.5)
Momentum
Strong Momentum(7.5)
Net Net
Not Undervalued (Net-Net)(0)
Quality
Moderate Quality(4)
Value
Overpriced(1)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.